Categories: Technology

Virtune AB (Publ) (“Virtune”) has completed the monthly rebalancing for September 2025 of its Virtune Crypto Altcoin Index ETP

 | Source: Virtune AB (Publ)

Stockholm, 1st of October 2025 – Virtune AB (Publ) (“Virtune”) today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm, Nasdaq Helsinki and Xetra (ISIN code SE0023260716).

In addition to the Virtune Crypto Altcoin Index ETP, Virtune’s product portfolio includes:

Virtune Bitcoin ETP
Virtune Staked Ethereum ETP
Virtune Stellar ETP
Virtune Staked Solana ETP
Virtune Staked Polkadot ETP
Virtune XRP ETP
Virtune Avalanche ETP
Virtune Litecoin ETP
Virtune Chainlink ETP
Virtune Arbitrum ETP
Virtune Polygon ETP
Virtune Staked Cardano ETP
Virtune Crypto Top 10 Index ETP SEK
Virtune Crypto Top 10 Index ETP EUR
Virtune Bitcoin Prime ETP
Virtune Coinbase 50 Index ETP
Virtune Staked Near ETP 

Index allocation as of 29th September (before rebalancing):

Avalanche: 13.19%
Solana: 11.70%
Polkadot: 10.51%
Bitcoin Cash: 10.16%
XRP: 10.06%
Stellar: 9.50%
Cardano: 9.44%
Litecoin: 9.33%
Chainlink: 8.49%
Uniswap: 7.62%

Index allocation as of 30th September (after rebalancing):

Solana: 10%
XRP: 10%
Cardano: 10%
Avalanche: 10%
Chainlink: 10%
Litecoin: 10%
Stellar: 10%
Uniswap: 10%
Bitcoin Cash 10%
Polkadot 10%

In connection with this month’s rebalancing, no change was made to the composition of the index.

The performance of the Virtune Crypto Altcoin Index ETP for September was +0.09%

The rebalancing is carried out according to the index that the ETP tracks, the Virtune Crypto Altcoin Index. The purpose of the monthly rebalancing is to reset the weights of each crypto asset to provide equal-weighted exposure to altcoins.

Virtune Crypto Altcoin Index ETP is the first of its kind in the Nordic region. It includes up to 10 leading alternative crypto assets (altcoins), excluding Bitcoin and Ethereum. Each altcoin is equally weighted to promote diversification; this structure allows investors to gain broad exposure to crypto assets beyond Bitcoin and Ethereum without being heavily concentrated in any single crypto asset.

If you, as an (institutional) investor, are interested in meeting with Virtune to explore how our ETPs can support your asset management strategy or to learn more about Virtune and our product offering, please feel free to contact us at hello@virtune.com. You can also visit www.virtune.com to learn more and subscribe to our newsletter for updates on upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a regulated Swedish digital asset manager and issuer of crypto exchange traded products listed on regulated European exchanges. Through regulatory compliance, strategic partnerships with leading industry players, and our experienced team, we empower global investors to access innovative and sophisticated investment solutions aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities September increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

GlobeNews Wire

Recent Posts

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

6 minutes ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

6 minutes ago

New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of…

6 minutes ago

President Droupadi Murmu Confers Kirti Chakra on Chandigarh University Alumnus Major Arshdeep Singh Gill

"Chandigarh University not only provides quality education but also instills a spirit of patriotism," says…

2 hours ago

Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock

Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual…

4 hours ago

Relativity Acquires Gavel to Extend its AI Platform for Legal Data Intelligence into Microsoft Word

News Summary:Relativity has acquired Gavel, an AI-native legal technology company whose solutions are used by…

4 hours ago